A Drug-Drug Interaction Study between AZD9668 and Warfarin to study the effect of AZD9668 on the metabolism and effect of Warfarin
Study identifier:D0520C00013
ClinicalTrials.gov identifier:N/A
EudraCT identifier:2010-022360-12
CTIS identifier:N/A
Terminated/Withdrawn
Official Title
A Phase I, open label, fixed sequence, single centre study in healthy volunteers to investigate the effects of repeated oral doses AZD9668 on the pharmacokinetics and pharmacodynamics of a single dose of warfarin
Medical condition
pharmacokinetics
Phase
Phase 1
Healthy volunteers
Yes
Study drug
AZD9668, Warfarin
Sex
Male
Actual Enrollment
0
Study type
Interventional
Age
18 Years - 55 Years
Date
Study Start Date: 01 Nov 2010
Estimated Primary Completion Date: 01 Dec 2010
Estimated Study Completion Date: 01 Dec 2010
Study design
Allocation: N/A
Endpoint Classification: Safety Study
Intervention Model: None
Masking: Open Label
Primary Purpose: Basic Science
Verification:
Verified 01 Jan 2013 by AstraZeneca Pharmaceuticals
Sponsors
AstraZeneca Pharmaceuticals
Collaborators
-
Inclusion and exclusion criteria
Loading...
No locations available
| Arms | Assigned Interventions |
|---|---|
| Experimental: Treatment A AZD9668 - 2 x30mg tablets | Drug: AZD9668 60 mg orally twice daily for 11 days |
| Experimental: Treatment B Warfarin - 10 x2.5 mg tablets | Drug: Warfarin 10 x 2.5 (25) mg orally once daily on day 1 and on day 14 |
Contacts
Investigators
Principal Investigator
Christopher D O’Brien
AstraZeneca R&D
